Role of miRNAs in cervical cancer: A comprehensive novel approach from pathogenesis to therapy

J Gynecol Obstet Hum Reprod. 2021 Nov;50(9):102159. doi: 10.1016/j.jogoh.2021.102159. Epub 2021 May 7.

Abstract

Human papillomaviruses (HPV) infection is a major causative agent and strongly associated with the development of cervical cancer. Understanding the mechanisms of HPV-induced cervical cancer is extremely useful in therapeutic strategies for primary prevention (HPV vaccines) and secondary prevention (screening and diagnosis of precancerous lesions). However, due to the lack of proper implementation of screening programs in developing countries, cervical cancer is usually diagnosed at advanced stages that result in poor treatment responses. Nearly half of the patients will experience disease recurrence within two years post treatment. Therefore, it is vital to identify new tools for early diagnosis, prognosis, and treatment prediction. MicroRNAs (miRNAs) are small non-coding RNAs, implicated in posttranscriptional regulation of gene expression. Growing evidence has shown that abnormal miRNA expression is associated with cervical cancer progression, metastasis, and influences treatment outcomes. In this review, we provide comprehensive information about miRNA and their potential utility in cervical cancer diagnosis, prognosis, and clinical management to improve patient outcomes.

Keywords: Biomarker; Cervical cancer; Diagnosis; Human papillomaviruses; Metastasis; microRNA.

Publication types

  • Review

MeSH terms

  • Early Detection of Cancer / methods
  • Female
  • Humans
  • MicroRNAs / administration & dosage
  • MicroRNAs / pharmacology*
  • Papillomavirus Infections / complications
  • Papillomavirus Infections / drug therapy
  • Prognosis
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / etiology*

Substances

  • MicroRNAs